<DOC>
	<DOCNO>NCT00970905</DOCNO>
	<brief_summary>Severe nausea and/or vomit patient receive radiotherapy upper abdomen common despite received pre-medication ondansetron , standard preventive treatment . This study aim reduce incidence significant nausea and/or vomit addition NK1-antagonist aprepitant standard ondansetron treatment . This study also assess safety tolerability prolong administration aprepitant 4 6 week period radiation treatment .</brief_summary>
	<brief_title>Effectiveness Aprepitant Addition Ondansetron Prevention Nausea Vomiting Caused Upper Abdominal Radiotherapy</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>1 . Any patient diagnosis malignancy localize upper abdomen require chemoradiation radiation alone . 2 . Receiving standardfractionation radiation therapy ( &gt; 40 Gy ) 3Dconformal radiation therapy IMRT field involve upper abdomen , either alone combine radiosensitizing 5FU , capecitabine , gemcitabine permit . 3 . Age &gt; 18 year old 4 . Life expectancy &gt; 3 month 5 . Performance status 02 inclusive 6 . No mild moderate hepatic impairment correspond ChildPugh Class A B , respectively ( ChildPugh score 5 9 ) . See Appendix V Child Pugh Classification . 7 . Women childbearing potential men must agree use adequate contraception abstinence effective barrier and/or nonhormonal contraception duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . 8 . Adequate organ reserve include : Absolute Neutrophil Count ≥ 1500/mcl , Hemoglobin ≥ 8.0 g/dl , platelet count ≥ 100,000/mcl , creatinine ≤ 2.0 , AST &amp; ALT ≤ 2.5 x ULN 9 . Baseline ECG show QTc value ≤ 480 millisecond 10 . Informed consent 1 . Use concomitant chemotherapy agent concurrently radiation therapy aside capecitabine , gemcitabine , 5fluorouracil ( none agent CYP 3A4 substrate ) . 2 . Baseline vomit control : Patients vomit nausea require antiemetic treatment within 24 hour prior initiation treatment . 3 . Scheduled receive treatment within 24 hour prior day one study period potential know antiemetic agent include limited serotonin antagonist aside ondansetron per study protocol , phenothiazine , butyrophenones , substitute benzamides , antihistamine , cannabinoids . Chronically used benzodiazepine may continue single nightly dose sleep . 4 . Any steroid use except topical steroid . Patients need systemic steroid treatment 7 day prior start chemoradiation therapy . 5 . Uncontrolled CNS tumor 6 . Other physical cause nausea vomit ( bowel obstruction ) relate chemoradiation administration 7 . Hypersensitivity either study agent 8 . Planned simultaneous administration investigational agent 9 . Pregnant nursing woman 10 . Patients take CYP3A4 inducer inhibitor would require discontinue use least 7 day prior initiation chemoradiation therapy . Examples CYP3A4 inducer include aminoglutethimide , carbamazepine , nafcillin , nevirapine , phenobarbital , phenytoin , rifampin , St. Johns Wort . Examples CYP3A4 inhibitor include azole antifungal , clarithromycin , diclofenac , doxycycline , erythromycin , imatinib , isoniazid , nefazodone , nicardipine , propofol , protease inhibitor , quinidine , telithromycin , verapamil . 11 . CYP3A4 substrates contraindicate . However , patient take CYP3A4 substrate caution consult physician minimize use , possible . Example substrate include benzodiazepine , calcium channel blocker , ranolazine , ergot derivative , mirtazapine , nateglinide , tacrolimus , venlafaxine . 12 . Concomitant use pimozide , terfenadine , cisapride , astemizole contraindicate per Emend™ [ 10 ] product circular dosedependent inhibition CYP 3A4 aprepitant could result elevated plasma concentration drug , potentially cause serious lifethreatening reaction . Patients take medication ineligible participate study unless discontinue least 7 day prior start aprepitant . 13 . Warfarin : Aprepitant may increase warfarin metabolism INR may decrease . Twice weekly monitoring INR recommend first 2week period radiation follow weekly monitoring subsequent week discontinuation aprepitant . Twice weekly monitoring recommend aprepitant discontinuation INR stabilize . 14 . Contraceptives ( estrogen progestin ) : Aprepitant may decrease plasma level estrogen progestin contraceptive . Contraceptive efficacy may reduce . A nonhormonal form contraception necessary treatment 1 month follow last dose aprepitant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Radiation</keyword>
	<keyword>Nausea</keyword>
	<keyword>Vomiting</keyword>
	<keyword>Ondansetron</keyword>
	<keyword>Aprepitant</keyword>
</DOC>